Your Partner for Growth, Hybridan

Hybridan

Your Partner for Growth

Our passion is raising growth capital for exciting, fast growth companies that want to take their business to the next level. We raise capital for companies both listed and unlisted in the most efficient manner possible and pride ourselves as being one of the few consistently profitable broking firms in the City. This has been achieved through a highly disciplined approach when seeking to create both corporate and institutional relationships.

Equity Bottom-Up

<ul>
<li>Alien Metals 0.125p £11.6m (UFO.L) The minerals exploration and development company has reported that its joint venture partner, West Coast Silver Limited has announced that it has entered into a non-binding Memorandum of Understanding with Artemis Resources Limited to evaluate the potential for Artemis' Radio Hill Processing Plant, located near Karratha, to process material sourced from West Coast's Elizabeth Hill Silver Mine in the Pilbara.</li>
<li>Digitalbox 4.75p £5.6m (DBOX.L) The mobile-first digital media business, with websites such as the Entertainment Daily, The Daily Mash, The Poke, The Tab and TV Guide updates on its Q4 period in 2025.</li>
<li>The Company expects EBITDA for the FY December 2025 to be significantly ahead of expectations while revenue to be broadly in line. </li>
</ul>


Alien Metals 0.125p £11.6m (UFO.L) The minerals exploration and development company has reported that its joint venture partner, West Coast Silver Limited has announced that it has entered into a non-binding Memorandum of Understanding with Artemis Resources Limited to evaluate the potential for Artemis' Radio Hill Processing Plant, located near Karratha, to process material sourced from West Coast's Elizabeth Hill Silver Mine in the Pilbara.
Digitalbox 4.75p £5.6m (DBOX.L) The mobile-first digital media business, with websites such as the Entertainment Daily, The Daily Mash, The Poke, The Tab and TV Guide updates on its Q4 period in 2025.
The Company expects EBITDA for the FY December 2025 to be significantly ahead of expectations while revenue to be broadly in line. 


Hybridan Small Cap Feast: 4 December 2025

<ul><li>The progress made by the operational expansion is evidenced by these finals to June 2025, which report a 46% increase in Revenue to £0.83m.</li><li>The loss before tax decreased 32% to £0.457m and year end cash is £0.461m.</li><li>We assume the accelerating trading momentum its maintained, suggesting a 10-12month cash runway at the lower burn rate.</li></ul>

The progress made by the operational expansion is evidenced by these finals to June 2025, which report a 46% increase in Revenue to £0.83m.The loss before tax decreased 32% to £0.457m and year end cash is £0.461m.We assume the accelerating trading momentum its maintained, suggesting a 10-12month cash runway at the lower burn rate.

Hybridan Research: Physiomics plc: Building Lasting Traction

<ul>
<li>After a sequence of contracts building from the core business, the YE Trading Update reports revenue higher than expectations, with a consequential reduction in losses and higher cash balances.</li>
<li>Assuming the momentum is maintained, it extends the cash runway to 12 months.</li>
<li>Revenue expectations for June 2025 are increased to £834k which is 46% ahead of FY June 24, while the Loss After Tax is 31% lower at £419k, than the comparable period. </li>
</ul>


After a sequence of contracts building from the core business, the YE Trading Update reports revenue higher than expectations, with a consequential reduction in losses and higher cash balances.
Assuming the momentum is maintained, it extends the cash runway to 12 months.
Revenue expectations for June 2025 are increased to £834k which is 46% ahead of FY June 24, while the Loss After Tax is 31% lower at £419k, than the comparable period. 


<ul><li>A further two contracts worth a combined £111,000 were announced this morning by the Company, as the total revenue pipeline continues to build.</li><li>These contracts with a new UK-based biopharmaceutical client have been won by the recently established Biometrics services division.</li><li>The Physiomics team have delivered over 100 commercial projects for drug development clients, including but not limited to, Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics and Cancer Research UK.</li></ul>

A further two contracts worth a combined £111,000 were announced this morning by the Company, as the total revenue pipeline continues to build.These contracts with a new UK-based biopharmaceutical client have been won by the recently established Biometrics services division.The Physiomics team have delivered over 100 commercial projects for drug development clients, including but not limited to, Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics and Cancer Research UK.

Hybridan Research: Physiomics plc: Synergistic Services

<ul><li>A contract extension has been signed with an existing large pharma client.</li><li>This builds upon the contract awarded in June 2024 and uses Physiomics’s proprietary Virtual Tumour platform to model the client’s targeted oncology agents in combination with other modalities helping inform dose and scheduling decisions.</li><li> The contract extension continues this work and supports the client’s expansion into new oncology indications.</li></ul>

A contract extension has been signed with an existing large pharma client.This builds upon the contract awarded in June 2024 and uses Physiomics’s proprietary Virtual Tumour platform to model the client’s targeted oncology agents in combination with other modalities helping inform dose and scheduling decisions. The contract extension continues this work and supports the client’s expansion into new oncology indications.

Hybridan Research: Physiomics plc: Building Relationships

United Kingdom

Physiomics plc develops computer simulation technology to understand and predict patient responses to pharmaceuticals.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Physiomics (PYC LN)

Hybridan Small Cap Feast: 4 December 2025

The Company expects EBITDA for the FY December 2025 to be significantly ahead of expectations while revenue to be broadly in line.

Hybridan

Hybridan Research: Physiomics plc: Building Lasting Traction

The progress made by the operational expansion is evidenced by these finals to June 2025, which report a 46% increase in Revenue to £0.83m. The...

Hybridan

Hybridan Research: Physiomics plc

Physiomics PLC (PYC) announced a trading update. We have published research on this which is attached and a snapshot of the research is below.

Hybridan

Hybridan Research: Physiomics plc: Synergistic Services

A further two contracts worth a combined £111,000 were announced this morning by the Company, as the total revenue pipeline continues to...

Hybridan

Hybridan Research: Physiomics plc: Building Relationships

A contract extension has been signed with an existing large pharma client. This builds upon the contract awarded in June 2024 and uses...

Hybridan

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)